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Frequency of CD19+CD24hiCD38hi
regulatory B cells is decreased in peripheral
blood and synovial fluid of patients with
juvenile idiopathic arthritis: a preliminary
study
Qianzi Zhao and Lawrence K. Jung*

Abstract
Background: To understand the relationship between regulatory B cells (Bregs) and juvenile idiopathic arthritis (JIA),
we analyzed the percentages of Bregs and their function in peripheral blood (PB) and synovial fluid (SF) of JIA patients.
Methods: Twenty-one JIA patients and 11 children with growing pain but without known rheumatic diseases as controls
were included. The B cell phenotype and intracellular production of IL-10 of Bregs were assessed by flow
cytometry. Mononuclear cells from PB and SF were stimulated to produce IL-10 in vitro for the identification of IL-10producing regulatory B cells.
Results: The percentage of CD24hiCD38hi Bregs in the PB of JIA patients was significantly decreased compared to that
in controls, and it was even lower in the SF of JIA patients compared to that in the PB. CD24hiCD38hi Bregs frequency
was significantly lower in the PB of RF-positive patients than in RF-negative patients. Frequency of IL-10-producing
regulatory B cells (B10 cells) was significantly lower in active JIA patients than that in inactive patients.
Conclusions: The inability of the host to produce enough regulatory B cells in PB and especially in SF of JIA patients
may contribute to the disease, especially the local inflammation.
Keywords: B lymphocytes, Cytokines, Inflammation, Juvenile idiopathic arthritis, Synovial fluid

Background
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children [1]. JIA is not one
disease. Rather, International League of Associations for
Rheumatology (ILAR) has classified it into 7 subtypes by
the number of joints and the type of extra-articular involvement [2]. Children with JIA are at risk for joint
damage, resulting in poor functional outcomes and decreased quality of life [3]. The pathogenesis of JIA is
not known yet. Recent studies have suggested that B
cells may have a role in these disorders. For example,
B cell-related genes were up-regulated in JIA patients
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[4], and memory B cells were increased in oligoarticular
and polyarticular JIA patients [5].
B cells are thought to play pathogenic role in the
immune responses, due to their ability (a) to produce
autoantibodies and (b) to act as antigen-presenting cells.
However, evidences have accumulated showing that B
cells can also down-regulate the immune response in both
mouse and human [6–15]. Genetically B cell-deficient
mice suffered more severe disease of experimental autoimmune encephalomyelitis [7]. When in vitro-activated B
cells were transferred into mice in the collagen-induced
arthritis mice model, they reduced the incidence and severity of disease [8, 13]. The term “regulatory B cells”,
shorted as Bregs, was used to define the B-cell subset with
regulatory properties [9].
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There are several possible mechanisms by which B cells
can regulate the immune responses [16–18]. Among these
mechanisms, the ability to produce regulatory cytokine
interleukin-10 (IL-10) is crucial in their regulatory function [8, 10, 12, 14, 16, 19–22]. Regulatory B cells that can
produce IL-10 are termed as B10 cells. IL-10 is an
anti-inflammatory cytokine that could regulate immune response by restoring Th1/Th2 balance and directly inhibit inflammatory cascade [23–25]. However,
the ability of Bregs to suppress immune responses was
not totally IL-10-dependent [10]. So B10 cells are a
subgroup of regulatory B cells.
There is no unique surface marker to identify Bregs.
CD19+CD24hiCD38hi [10, 14, 26, 27] and CD19+CD5+CD1dhi
[28–31] have been used in different studies. It was reported that the majority of the CD19+CD5+CD1dhi B
cells were contained within the CD24hiCD38hi B cell
subset [14]. Therefore, we utilized CD19+CD24hiCD38hi
as a surface marker for Bregs in this study.
Deficiency of Bregs may lead to autoimmune diseases. Indeed, decreased Breg cells number or function have been
identified in rheumatoid arthritis (RA) [32, 33], systemic
lupus erythematosus (SLE) [10, 30], anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis [26, 34].
Transferred regulatory B cells could reduce disease activity
in mouse arthritis model [8, 13]. Therefore, it is reasonable
to hypothesize that Bregs may play a role in the pathogenesis of JIA. In this study, we test this hypothesis by
analyzing the percentages of Bregs and their ability to
produce IL-10 in peripheral bloods and synovial fluids
of JIA patients.

Methods
Patients and controls

A total of 32 patients from the Division of Rheumatology of
Children’s National Medical Center were recruited in this
study, including 21 JIA patients (13 poly-JIA, 5 oligo-JIA, 2
systemic, 1 psoriatic) and 11 children with growing pain
but no known rheumatic diseases as controls. JIA patients were diagnosed according to the ILAR criteria
[2]. Growing pain was diagnosed after known diseases
were excluded with negative immunologic test findings.
Peripheral blood (PB) samples were collected from the
JIA patients and controls. One patient was followed
longitudinally and PB samples were collected at both active and inactive phase. Synovial fluid (SF) samples were
collected from 4 JIA patients who required intra-articular
steroid injection as a part of treatment protocol. Of these
subjects, both PB and SF samples were collected from 1
patient on the same day. Disease activity was assessed and
inactive disease was defined according to Wallace’s criteria
[35]. Patients who didn’t meet the definition for inactive
disease were defined as having active disease. Demographic and clinical data of the patients were collected.
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The study was conducted in compliance with the Helsinki
Declaration and ethical approval was obtained from the
Institution Review Board of Children’s National Medical
Center (Pro00005055). All patients were enrolled after
obtaining informed consent from parents and assent
from patients older than 7 years old.
Human cell isolation and generation of B10 cells

Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMC) were isolated
from heparin-treated PB and SF by Ficoll-Paque Plus
(GE Healthcare, Uppsala, Sweden) gradient centrifugation.
PBMCs and SFMCs were cultured in RPMI 1640 containing L-glutamine (Life Technologies, Paisley, UK) supplemented with 100 U/μg/ml penicillin/streptomycin (Life
Technologies, Paisley, UK), and 10% fetal bovine serum in
48-well flat-bottom plates for 48 h at 37 °C in 5% CO2. According to previous study [12], combination of CpG and
CD40L stimulation could generate the most of B10 cells in
human. Therefore, the cultured cells were stimulated with
10 μg/ml CpG ODN2006 (Invivogen, San Diego, USA) and
1 μg/ml CD40L (R&D Systems, Minneapolis, USA),
or with phosphate-buffered saline (PBS) as control.
For the last 6 h, 50 ng/ml phorbol myristate acetate
(PMA) and 1 μg/ml ionomycin (Sigma-Aldrich, USA)
were added to the stimulated cells; Brefeldin A (BFA,
eBioscience, San Diego, USA), Golgi transport blocker,
was added to all wells.
Surface markers and intracellular IL-10 detection

The following anti-human monoclonal antibodies (mAbs)
were used for surface markers and intracellular IL-10
detection: fluorescein isothiocyanate (FITC)-conjugated
anti-CD19; phycoerythrin (PE)-conjugated anti-CD24 (BD
Biosciences, San Diego, USA); PE-Cyanine7-congugated
anti-CD38; allophycocyanin (APC)-conjugated anti-IL-10
(Biolegend, San Diego, USA); and isotype-matched and
fluorochrome-matched control antibodies. Cells were
stained with combinations of CD19-FITC, CD24-PE and
CD38-PE-Cy7 mAbs for surface phenotype. For intracellular
IL-10 detection, cultured cells were washed, fixed, permeabilized, and stained with IL-10-APC mAb. APC-conjugated
isotype control was used for gate setting for cytokine expression. Stained cells were analyzed on an eight-color FACSCanto II flow cytometer (BD Biosciences) using FACSDiva
software (BD Biosciences).
Statistical analysis

Statistical analyses were performed using GraphPad
Prism Version 6 (GraphPad Software, La Jolla, CA,
USA). Chi-square tests were performed for discrete variables. Student t test was used for parametric test when
comparing two groups with equal variances. Welch’s t
test was used for parametric test when comparing two
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groups with unequal variances. Mann-Whitney U-test
was used for non-parametric test when comparing two
groups. Spearman’s correlation was performed to determine correlation. A p value of < 0.05 was considered
statistically significant.

Results
Clinical characteristics of study subjects

The demographic and clinical features of 21 JIA patients
and 11 controls are summarized in Table 1. There was
no significant difference between the 2 groups with the
exception that none of the control subjects were positive
for rheumatoid factor. Table 2 shows the demographic
and clinical features of 4 JIA patients from whom SF
samples were collected.
CD24hiCD38hi B cell levels were reduced in PB of JIA
patients and even lower in SF

Peripheral blood and synovial fluid mononuclear cells
from subjects were phenotypically analyzed by flow cytometry for their expression of CD19, CD24, and CD38
surface markers. B cells were defined as CD19+ lymphocytes. Within CD19+ B cells gate, CD24hiCD38hi cells
were defined as CD24hiCD38hi Bregs. The gate strategy
for CD19+CD24hiCD38hi cells was illustrated by a representative staining of cells in a healthy control subject
(Fig. 1a). The percentages of CD24hiCD38hi Bregs subset
were calculated as the ratios of gated targeted cells to
total CD19+ B cells. The results were expressed as mean
values ± standard deviation (SD).
Table 1 Demographic and clinical features of JIA patients and
controls
Characteristics

JIA patients

Controls

Number

21a

11

Gender, Female:Male (n:n)

12:9

6:5

Age (years)

10.9 ± 1.1

12.4 ± 1.1

Duration of disease (years)

3.7 ± 0.7

NA

Treatment when sampled; n

NSAID, MTX,
None; 5
anti-TNF;4
NSAID alone;6
NSAID, Anti-TNF; 3
MTX, anti-TNF;1
Anti-TNF;4
NSAID; 7
None; 2b

RF Pos:Neg (n)

4:14c

0:11

PB White blood cell count (× 109/L) 7.62 ± 0.66

6.19 ± 0.54

PB Lymphocyte count (×109/L)

2.24 ± 0.12

a

3.06 ± 0.31

One patient was sampled at both active and inactive phase
Patients were sampled when diagnosis was made and before treatment was given
RF was not tested in 3 patients
JIA juvenile idiopathic arthritis, MTX methotrexate, NA not applicable, Neg
negative, NSAID non-steroidal anti-inflammation drug, Pos positive, RF
rheumatoid factor, TNF tumor necrosis factor, PB peripheral blood
b
c

As shown in Fig. 1b, we observed a significant decrease
in the levels of CD24hiCD38hi Bregs in the PB of JIA patients compared to those in controls (16.11 ± 1.09% vs.
23.83 ± 1.73%, p < 0.001). An even more significant decrease was seen in the SF of JIA patients compared to
those in the PB (3.23 ± 1.92% vs. 16.11 ± 1.09%, p <
0.0001). The data of PB and SF samples from the same
patient supported this result. The percentage of
CD24hiCD38hi Bregs in the SF was lower than that in
the PB of the same patient collected on the same day
(1.41% vs. 13.00%) (Fig. 1c). Of note, there was no significant difference of B cells percentages in PB between JIA
patients and controls (15.22 ± 1.28% vs. 16.35 ± 1.22, p =
0.5788). However, B cells population in SF was significantly decreased compared with PB (1.47 ± 0.27% vs.
15.22 ± 1.28%, p = 0.0001). Probably due to this decrease,
CD24hiCD38hi Bregs subset was almost absent in SF
mononuclear cells (SFMCs). In peripheral blood mononuclear cells (PBMCs) of JIA patients, the percentage of
CD24hiCD38hi Bregs was 2.41 ± 0.27%, while this percentage was 0.04 ± 0.02% in SFMCs, which was highly significant (p = 0.0004).
We next examined the frequencies of CD24hiCD38hi
Bregs in poly-JIA and non-poly-JIA patients. As in
total JIA patients, the frequencies of CD24hiCD38hi
Bregs in poly-JIA and non-poly-JIA patients were significantly decreased compared with controls (p < 0.01
and p < 0.05, respectively) (Fig. 1b). No significant difference of frequency of CD24hiCD38hi Bregs was observed between poly and non-poly JIA patients (p =
0.6177).
Next, we examined whether CD24hiCD38hi Bregs
level correlated with disease activity or treatment.
Treatments for all patients are shown in Table 1. As
shown in Fig. 2a, there was no significant difference
in the CD24hiCD38hi Bregs levels between active JIA
and inactive JIA patients (p = 0.6238). In addition, no
difference of CD24hiCD38hi Bregs level was observed
between patients with and without methotrexate(MTX)
or TNF antagonist treatment (p = 0.1358, p = 0.1469,
respectively) (Table 3).

CD24hiCD38hi Breg cells levels were associated with RF in
PB of JIA patients

We further examined the possible correlations between
the frequencies of CD24hiCD38hi Bregs and laboratory
parameters. As shown in Fig. 2b, a significantly lower frequency of CD24hiCD38hi Bregs was found in the PB of
RF-positive patients than in RF-negative patients (10.81 ±
1.80% vs. 17.11 ± 1.14%, p < 0.05). However, no significant correlation was found between the frequencies of
CD24hiCD38hi Bregs and ESR (Spearman’s r = − 0.5108,
p = 0.0519) (Fig. 2c).
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Table 2 Demographic and clinical features of JIA patients from whom synovial fluid samples were collected
No.

Subtype

Gender

Age (years)

Duration of disease (years)

RF

Treatment when sampled

1

Oligoarticular

M

1.2

0.1

Neg

Nonea

2

Oligoarticularb

M

8

2.1

Neg

NSAID

3

Polyarticular

F

8

4

Neg

NSAID

4

Psoriatic

M

15

1

Neg

NSAID, MTX, anti-TNF

a

This patient was sampled when diagnosis was made and before treatment was given
b
Peripheral blood sample was collected from the patient the same day synovial fluid sample was collected
F female, JIA juvenile idiopathic arthritis, M male, MTX methotrexate, NA not applicable, Neg negative, NSAID non-steroidal anti-inflammation drug, RF rheumatoid
factor, TNF tumor necrosis factor

IL-10-producing regulatory B cells (B10 cells)
percentages in JIA patients was increased in the polyJIA patients although had no difference in JIA patients
as a group

As a subgroup of Bregs, B10 cells level was also examined
in PB and SF of JIA patients and PB of controls. By ex vivo

stimulation of CpG + CD40L for 48 h and PMA + ionomycin for the last 6 h, intracellular production of IL-10 by
CD19+ B cells was observed, while few B cells produced
IL-10 when cultured with PBS only (Fig. 3a). A representative experiment showing intercellular IL-10 staining of B
cells in a JIA patient is shown in Fig. 3a.

a

b

c

Fig. 1 Frequencies of CD24hiCD38hi Bregs in juvenile idiopathic arthritis (JIA) patients and controls. a The gate strategy for CD19+CD24hiCD38hi
cells in the peripheral blood (PB) of one control. B cells were defined as CD19+ lymphocytes. Within CD19+ B cells gate, CD24hiCD38hi cells were
defined as CD24hiCD38hi Bregs. b CD24hiCD38hi Bregs frequencies in total B cells were compared in PB of total, poly and non-poly JIA patients,
synovial fluid (SF) of JIA patients, and PB of controls. The frequency of CD24hiCD38hi Bregs in the PB of total JIA patients was significantly decreased
compared to those in controls (p = 0.0007), and it was even much lower in the SF of JIA patients compared to that in the PB (p < 0.0001). c The
percentage of CD24hiCD38hi Bregs in the SF of one patient was lower than that in the PB of the same patient collected on the same day. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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a

b

c

d

e

f

Fig. 2 Correlation between frequencies of Bregs and different laboratory parameters. a. No difference of CD24hiCD38hi Bregs frequencies was found
between active and inactive JIA patients (8.07 ± 2.48% vs. 7.50 ± 1.52%, p = 0.8494). b The frequency of CD24hiCD38hi Bregs was significantly lower in RFpositive JIA patients than in RF-negative patients (10.81 ± 1.80% vs. 17.11 ± 1.14%, p = 0.0199). c No significant correlation was found between frequencies
of CD24hiCD38hi Bregs and ESR (Spearman’s r = − 0.5108, p = 0.0519). d No significant correlation was found between frequencies of CD24hiCD38hi Bregs
and IL-10 producing regulatory B cells (B10 cells) (Spearman’s r = 0.0883, p = 0.7438). e No significant correlation was found between frequency of B10 cells
and ESR (Spearman’s r = − 0.2549, p = 0.3073). f No difference of levels of B10 cells was found between RF-positive and RF-negative patients (8.07 ± 2.48%
vs. 7.50 ± 1.52%, p = 0.8494). Bregs, regulatory B cells; ESR, erythrocyte sediment rate; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor. * p < 0.05

Unlike the remarkable reduction of CD24hiCD38hi
Bregs levels in JIA patients, there was no significant difference of B10 cells levels between the PB of JIA patients
and controls (7.43 ± 0.99% vs. 4.56 ± 0.71%, p = 0.0527)
(Fig. 3b). In SF of JIA patients the B10 cells level was

not significantly different from that in PB (4.32 ± 1.14%
vs. 7.43 ± 0.99%, p = 0.2419) either. However, when we
examined B10 cells frequency in the poly-JIA subgroup,
we noticed a significant increase compared with controls
(p = 0.0249) (Fig. 3b).

Table 3 Regulatory B cells percentages in different treatment subgroups
No DMARD

DMARD

p value

No anti-TNF

Anti-TNF

p value

B cells (%)

14.96 ± 0.87 (n = 14)

16.19 ± 4.48 (n = 6)

0.7006

13.41 ± 1.07 (n = 8)

16.61 ± 2.20 (n = 12)

0.2757

CD24hiCD38hi Bregs
(% in B cells)

17.11 ± 1.12 (n = 11)

13.38 ± 2.43 (n = 4)

0.1358

18.08 ± 1.42 (n = 6)

14.80 ± 1.45 (n = 9)

0.1469

B10 cells (% in B cells)

7.25 ± 1.14 (n = 14)

7.73 ± 2.30 (n = 5)

0.8408

6.16 ± 1.48 (n = 7)

8.09 ± 1.34 (n = 12)

0.3683

Bregs regulatory B cells, B10 cells IL-10 producing regulatory B cells, DMARD disease-modifying antirheumatic drug, JIA juvenile idiopathic arthritis, PB peripheral
blood, SF synovial fluid, TNF tumor necrosis factor
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a

b

c

Fig. 3 Frequencies of IL-10 producing regulatory B (B10) cells in juvenile idiopathic arthritis (JIA) patients and controls. a Representative
intracellular IL-10 staining in B cells in peripheral blood (PB) of one JIA patient with/without stimulation of CpG + CD40L for 48 h and phorbol 12myristate 13-acetate+ionomycin+brefeldin A (PIB) for the last 6 h (right). Few B cells produced IL-10 when cultured with PBS only (left). Isotype
controls were used to set up the negative population (lower). b Comparison of B10 cells frequencies in PB of different groups of JIA patients,
synovial fluid (SF) of JIA patients, and PB of controls (left). c Comparison of B10 cells frequencies in active and inactive patients. BFA, brefeldin A;
CD40L, CD40 ligand; Iso, isotype; PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PIB, phorbol 12-myristate 13-acetate
+ionomycin+brefeldin A; poly-JIA, polyarticular juvenile idiopathic arthritis. *p < 0.05, **p < 0.01,***p < 0.001

B10 cells frequency in JIA patients was associated with
disease activity

We then examined whether the frequencies of B10 cells
correlate with disease activity. Significantly lower frequency of B10 cells was found in active JIA patients
compared with that in inactive patients (5.77 ± 1.13% vs.
9.72 ± 1.49%, p < 0.05), while no significant difference

was found between active patients and controls (5.77 ±
1.13% vs. 4.56 ± 0.71%, P = 0.3762) (Fig. 3c). One patient
was followed longitudinally and the same trend was
noted: the percentage of B10 cells increased from 2.93%
when active and increased to 5.96% when inactive, supporting the association between B10 level and JIA disease activity.
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Same trend was also found in poly-JIA patient. As
shown in Fig. 3c, when we subdivided poly-JIA patients
into active and inactive subgroups, we observed a significantly lower frequency of B10 cells in the active poly-JIA
subgroup compared with inactive poly-JIA subgroup
(6.00 ± 1.48 vs. 11.87 ± 1.56, p = 0.0239), while no significant difference was found between B10 cells frequencies
in the active poly-JIA subgroup and controls (p = 0.3531).
When we compared the frequencies of B10 cells with
different treatment groups, no significant difference was
observed between groups with and without MTX or TNF
antagonist (p = 0.8408, p = 0.3683, respectively) (Table 3).
There is no notable correlation between Bregs levels and
B10 cells levels

Since B10 cells are a specific subgroup of Bregs, we examined whether there was a correlation between the
level of CD24hiCD38hi Bregs and the level of B10 cells in
JIA patients. As shown in Fig. 2d, no notable correlation
was observed (p = 0.7438). Also, there was no correlation between the level of B10 cells and ESR level (p =
0.3073) (Fig. 2e). No difference of levels of B10 cells was
found between RF-positive and RF-negative patients
(8.07 ± 2.48% vs. 7.50 ± 1.52%, p = 0.8494) (Fig. 2f ).

Discussion
In this study, we found that CD24hiCD38hi Bregs percentage was remarkably lower in the peripheral blood of
JIA patients compared with control, and it was even
much lower in the SF of JIA patients. This decrease was
seen in both the poly-JIA and nonPoly-JIA groups. Also,
reduced PB CD24hiCD38hi Bregs levels were associated
with patients with positive RF. In contrast, B10 cells, a
special subgroup of regulatory B cells that could produce
IL-10, were not reduced in PB and SF of JIA patients
compared with controls, but it was associated with disease activity. The B10 cells level was significantly lower
in active JIA patients than in inactive patients; this finding is also true in the poly-JIA subgroup.
Peripheral blood CD24hiCD38hi Bregs deficiencies have
been described in several autoimmune diseases, including
RA [32, 33], SLE [10, 30] and ANCA-associated vasculitis
[26, 34]. In this study, we have not only showed a decreased
level of CD24hiCD38hi Bregs in the PB of JIA patients, but
also the deficiency of these cells in the synovial fluid of JIA
patients. In SFMCs, CD24hiCD38hi Bregs subset was almost
absent and was as low as 1.6% of that in the PBMCs.
Taken together, those findings suggest that CD24hiCD38hi
Bregs may be critical in controlling inflammation in JIA
and the inability of the host to produce enough of them in
PB and especially in SF may contribute to the disease.
Moreover, even if the patients had inactive disease, the
CD24hiCD38hi Bregs level was still significantly lower than
control, and there was no significant difference between
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active and inactive patients, suggesting that the reduced
CD24hiCD38hi Bregs was inherent in the JIA patients.
In addition, we noticed that in the RF-positive patients,
the CD24hiCD38hi Bregs level was lower than that in
RF-negative patients.This suggests that Bregs may play a
role in regulating the production of autoantibody such as
RF. This concept is supported by a murine model of transplantation tolerance, wherein the production of alloantibodies was significantly reduced by adoptive transfer of
Bregs [36].
It is interesting that despite the decrease of CD24hiCD38hi
Bregs, B10 cells levels were not decreased in PB and SF of
JIA patients compared with controls, and there was no
notable correlation between CD24hiCD38hi Bregs levels and
B10 cells levels in JIA patients. This result might suggest
that although CD24hiCD38hi Bregs were numerically deficient in JIA patients, their inherent ability to produce IL-10
was not compromised. This lack of correlation between
phenotypically defined Breg cell subset and B10 cells
has already been reported in adults [33, 34, 37]. The
reason might be that B10 cells are not restricted to the
CD24hiCD38hi B cell subset, and other B cells subsets
might contain more of them [33].
Interestingly, we observed an association of disease
activity with B10 cells in JIA patients, although we didn’t
observe a difference between the levels of B10 cells in
PB of total JIA patients and controls. The B10 cells frequency was significantly lower in all active patients than
in inactive patients. This was also true in poly-JIA subgroup of patients. The increase in the B10 cells in inactive
patients may be indicative of a successful pathophysiological response to the inflammation. Kalampokis et al.
[38] have recently reported the number of B10 cells in JIA
patients and in health children. Similar to our result, they
didn’t find a significant difference of B10 levels between
JIA group and controls. However, they didn’t observe a
significant difference of total IL-10-producing B cells
levels between active and inactive patients. This discrepancy may be due to different definition for “inactive disease”. In our study, we used the more strict criteria to
define inactive disease as an active joint count of 0, absence of uveitis and a PGA < 10 mm with normal ESR
[35], while Kalampokis et al.. used only one criterion of
PGA < 10 mm. Our result suggests that the status of disease activity is a very important consideration when one
studies the B10 cells in JIA.
Our study showed that patients with active JIA had less
B10 cells frequency compared with patients with inactive
disease. This is consistent with the results in patients with
RA [14, 33]. We didn’t find a correlation between
CD24hiCD38hi Bregs or B10 cells levels and MTX or
TNF treatment in JIA patients. This is consistent with
the result of Kalampokis et al... This result suggests that
MTX or TNF treatment might not help to correct the
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altered immunological balance in JIA patients. Glaesener
et al showed that the CD24hiCD38hi transitional B cells
was significantly decreased in patients receiving MTX
compared with untreated patients [39]. In our study, we
didn’t see a significant difference of CD24hiCD38hi B cells
percentages between patients with and without MTX
treatment. The difference in our conclusion may be rooted
in the fact that their study-subject composition was different from ours. In Glaesener et al’s study, the dominant
group of patients was oligo-JIA patients (68%). In our
study, poly-JIA patients were the dominant group (62%).
Our poly-JIA patients required both MTX and anti-TNF
treatment while none receiving only MTX; whereas in
their study, the group receiving just MTX were predominantly oligo-JIA subjects (71%). Due to our small sample
size, we could not perform detailed analysis of effect of
MTX alone.

Conclusions
 Regulatory B cells a relatively new area of research










compared with regulatory T cells. In recent years,
emerging data support their importance in diverse
normal and pathologic processes.
Our study showed for the first time that
CD24hiCD38hi Bregs percentage was remarkably
lower in the peripheral blood of JIA patients
compared with healthy control, and it was even
lower in the synovial fluid of JIA patients.
Also, the regulatory B10 cells level was inversely
correlated with disease activity.
Our study suggests that the inability of the host to
produce enough regulatory B cells in PB and
especially in SF of JIA patients may contribute to the
local inflammation.
These findings provide new insights in the pathogenesis
of autoimmune diseases and may suggest a novel
approach to control the disease processes.
One caveat about our finding is that the numbers of
SF samples and subgroup subjects were small in this
preliminary study. Further studies with a larger
sample size and more longitudinal follow up will be
needed to confirm the findings reported here.
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